When to consider endoscopic ablation therapy for Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 26, Issue 4, 2010, Pages 361-366

  Shaheen, Nicholas J ^a,b   Frantz, David J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ablation; Barrett's esophagus; Dysplasia; Photodynamic therapy; Radiofrequency

Indexed keywords

ANALGESIC AGENT;

BARRETT ESOPHAGUS; CANCER INCIDENCE; DISEASE COURSE; ENDOSCOPIC SURGERY; ESOPHAGUS HEMORRHAGE; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; FOLLOW UP; GASTROINTESTINAL DYSPLASIA; HEALTH CARE COST; HUMAN; OPERATION DURATION; PATIENT SELECTION; PHOTODYNAMIC THERAPY; RADIOFREQUENCY ABLATION; REVIEW; SQUAMOUS CELL CARCINOMA; THORAX PAIN; TREATMENT OUTCOME; CATHETER ABLATION; COST BENEFIT ANALYSIS; ECONOMICS; ESOPHAGOSCOPY; PHOTOCHEMOTHERAPY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; TIME;

BARRETT ESOPHAGUS; CATHETER ABLATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ESOPHAGOSCOPY; HUMANS; PATIENT SELECTION; PHOTOCHEMOTHERAPY; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 77954142407     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32833ad543     Document Type: Review

References (34)

1. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62:488-498.
2. Sharma VK, Jae Kim H, Das A, et al. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol 2009; 104:310-317.
3. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8:23-29.
4. Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned. Surg Endosc 2009; 23:2175-2180.
5. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360:2277-2288.
6. Eldaif SM, Lin E, Singh KA, et al. Radiofrequency ablation of Barrett's esophagus: short-term results. Ann Thorac Surg 2009; 87:405-410; discussion 410-411.
7. Vassiliou MC, von Renteln D, Wiener DC, et al. Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation. Surg Endosc 2010; 24:786-791.
8. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68:35-40.
9. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40:359-369.
10. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68:867-876.
11. Hernandez JC, Reicher S, Chung D, et al. Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy 2008; 40:388-392.
12. Sharma VK, Kim HJ, Das A, et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008; 40:380-387.
13. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40:370-379.
14. Sharma P, Wani S, Rastogi A. Endoscopic therapy for high-grade dysplasia in Barrett's esophagus: ablate, resect, or both? Gastrointest Endosc 2007; 66:469-474.
15. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radio-frequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus 2007; 20:516-522.
16. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65:185-195.
17. Dumot JA, Vargo JJ 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70:635-644.
18. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333-338.
19. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:235-244; quiz e32.
20. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gas-trointest Endosc 2007; 66:460-468.
21. Wouter LC, Wilda R, Brenda E, et al. Low-grade intra-epithelial in Barrett's esophagus: over-diagnosed but underestimated. Gastrointest Endosc 2008; 67:AB181.
22. Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastro-enterol 2010 [Epub ahead of print].
23. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007; 26:1465-1477.
24. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007; 133:34-41.
25. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007; 133:403-411.
26. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007; 4:e67.
27. Kubo A, Block G, Quesenberry CP Jr, et al. Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr Cancer 2009; 61:607-616.
28. Kubo A, Levin TR, Block G, et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009; 136:806-815.
29. Smith KJ, O'Brien SM, Green AC, et al. Current and past smoking significantly increase risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7:840-848.
30. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004; 53:1736-1744.
31. Das A, Wells C, Kim HJ, et al. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus. Endoscopy 2009; 41:400-408.
32. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009; 136:; 2101-2114, e1 -e6.
33. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128-1137.
34. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007; 132:1226-1233.